Nutraceuticals Contract Packing in Australia: TGA, GMP and What Brands Need to Know

Nutraceuticals contract packing in Australia is the outsourced finishing of vitamins, minerals, herbal supplements, protein powders, sports nutrition and other complementary medicines through a partner facility that holds a Therapeutic Goods Administration (TGA) manufacturing licence. The work covers bottling, blistering, sachet filling, compliance labeling, kitting, tamper-evident sealing and pallet preparation, all conducted under the PIC/S Guide to Good Manufacturing Practice and tied to a specific entry on the Australian Register of Therapeutic Goods (ARTG).

As of 2026, almost every supplement sold in Australia is regulated as a therapeutic good, not a food. That distinction changes everything about how the product is packed, labeled, traced and released. Brands that treat supplements like food packaging end up with non-compliant SKUs sitting in customs holds or pulled from retailer shelves.

This guide covers the TGA framework, the GMP requirements your co-packer must meet, what TGO 92 demands on the label, indicative cost and timeline ranges, and the questions to ask before signing with any nutraceuticals co-packer in Australia.

Australia regulates supplements under the Therapeutic Goods Act 1989, administered by the TGA. They are not foods regulated by Food Standards Australia New Zealand (FSANZ), even when they look like food (protein bars with therapeutic claims, fortified powders, gummy multivitamins). They are also not full pharmaceuticals subject to the same scrutiny as prescription drugs.

They sit in their own category called complementary medicines, which includes vitamins, minerals, herbs, nutritional supplements, homeopathic medicines and aromatherapy products. The category is regulated proportionally to risk, but the GMP and labeling rules still apply.

The practical implication for contract packing is that a facility certified for food packing under HACCP cannot lawfully pack a Listed complementary medicine. The facility needs a current TGA manufacturing licence covering the dose form being packed (oral solid, oral liquid, powder, soft gel, etc.). Sponsors who get this wrong discover the gap during their first ARTG audit, and the discovery is expensive.

The TGA splits complementary medicines into two streams, identified by the prefix on the product's ARTG number. The split determines what claims you can make, how long approval takes and what evidence is required.

Listed medicines (AUST L) cover low-risk products using only pre-approved ingredients from the Permissible Ingredients Determination. The sponsor self-certifies safety and efficacy at listing. Approval is typically issued within days of submission. About 95% of supplements sold in Australia are Listed. Claims are restricted to general health maintenance, vitamin and mineral supplementation and traditional indications.

Listed Assessed (AUST L(A)) is a middle tier introduced in 2018 for products making intermediate-level claims with TGA pre-market efficacy assessment. Adoption has been modest because the timeline and cost narrow the gap to AUST R.

Registered medicines (AUST R) cover higher-risk products and any complementary medicine making a specific therapeutic claim beyond traditional or general use. The TGA assesses safety, quality and efficacy before listing. Timelines run 12 to 18 months and the application fee alone exceeds AUD $50,000.

For your co-packer, the AUST L vs AUST R distinction usually does not change the facility requirement, both need GMP, but it changes batch management, record retention and release procedures. AUST R products often require additional stability data tied to the specific packing run, including primary container and closure validation.

Any facility packing a complementary medicine in Australia must hold a current TGA manufacturing licence issued by the Office of Manufacturing Quality. The licence is product- and dose-form-specific. A facility licensed for tablets and capsules is not automatically licensed for liquids or powders.

The technical standard is the PIC/S Guide to Good Manufacturing Practice for Medicinal Products (PE009). PIC/S is the Pharmaceutical Inspection Co-operation Scheme, the international body that harmonises GMP across regulators including the TGA, MHRA (UK), Health Canada and the EMA. Annex 7 of PE009 is specific to herbal medicinal products.

A GMP audit covers everything a sponsor would expect: facility design and segregation, qualification and validation of equipment, cleaning validation between batches, change control, deviation management, complaint handling, recall procedures, training records and documented batch packing records. TGA inspections happen at minimum every three years for licensed sites and unannounced inspections are common.

For sponsors choosing a partner, three things matter most. First, ask for the manufacturing licence number and confirm it on the TGA's public Licensed Manufacturers database. Second, ask which dose forms the licence covers. Third, ask for the date and outcome of the most recent TGA inspection. A site whose last GMP audit was more than three years ago is overdue.

For a broader view of how GMP compares to other certifications a co-packer might hold, see our guide to product labeling compliance.

Therapeutic Goods Order No. 92 (TGO 92) is the mandatory standard for labels on non-prescription medicines, including all complementary medicines. It came into full force in July 2023 and replaced the older TGO 69. Every nutraceutical packed for the Australian market must comply with TGO 92, regardless of where the product is manufactured.

A compliant TGO 92 label includes:

- Active ingredient name and quantity per dosage unit, in a prominent format on the front of the pack

- AUST L, AUST L(A) or AUST R number clearly displayed

- Sponsor name and Australian address of the entity holding the ARTG entry

- Batch number and expiry date in legible, indelible marking

- Storage conditions including temperature range

- Warnings and contraindications as required by the Required Advisory Statements for Medicine Labels (RASML)

- Net quantity in metric units

The rules also cover minimum font sizes (1.5mm for active ingredient information, 2mm for warnings on outer packs), contrast ratios and the placement of mandatory text blocks. Specialty assembly work for retail-ready presentations like multi-pack promotions or gift sets adds another layer, because the outer pack also has to carry compliant information when it is the unit sold to the consumer.

Label design errors are the single most common compliance failure during TGA inspection. A reliable co-packer will run a pre-production label proof against the TGO 92 checklist and flag issues before the print run, not after.

Tamper-evident packaging is mandatory for most oral nutraceuticals under TGO 92, and the standard accepted is AS 2828 or equivalent. Common tamper-evident solutions include induction-sealed liners under the bottle cap, shrink bands across the closure, blister packs with no separate access point, and sachet-style sealing for powders. Whichever method is chosen, it must be documented in the product's ARTG entry and the verification procedure must form part of the batch packing record.

Batch records under PIC/S GMP must capture, at minimum: the materials used (with their own batch and supplier traceability), the equipment used, the operators, the in-process checks and results, the start and finish times, the yield reconciliation, the deviation log if any, and the QA sign-off authorising release. These records have to be retained for the shelf life of the product plus one year, or five years from the date of release, whichever is longer.

The practical test of a co-packer's batch management is straightforward: ask them to retrieve the full packing record for an arbitrary batch from twelve months ago. If it takes more than a working day, their record system is paper-heavy and a recall would be slow. Modern co-packers run digital batch records, with materials, counts and quality checks logged at the workstation in real time. CleverPak Connect captures this digitally as standard, so a recall trace runs in minutes rather than hours.

Pricing for nutraceuticals contract packing in Australia varies with dose form, batch size, primary pack format and the level of compliance labeling required. The figures below are typical commercial ranges seen across the Australian market in 2026 for Listed complementary medicines packed under GMP. They are indicative, not quotes.

Evaluating a co-packer for complementary medicines goes well beyond the per-unit rate. The wrong choice surfaces months later as a TGA inspection finding, a recall, or a retailer rejecting a delivery for non-compliant labels. Use this checklist before signing with any partner.

• Current TGA manufacturing licence covering the specific dose form (tablet, capsule, soft gel, powder, liquid, sachet)
• Verifiable PIC/S GMP audit history with dates of TGA inspections and outcomes available on request
• TGO 92 label review process before any print run, including font size, RASML warnings, batch and expiry placement
• AS 2828-compliant tamper evidence applied at the primary pack, with verification documented in the batch record
• Digital batch records with materials, in-process checks and QA release traceable on demand, not paper-only systems
• Allergen and cross-contamination controls including documented changeover procedures between products containing peanuts, tree nuts, milk, soy, gluten, fish or shellfish-derived ingredients
• Retail-ready packing capability for Australian supermarket and pharmacy compliance, including barcode and shelf-ready carton requirements
• Cold chain or controlled-temperature handling if your product contains probiotics, fish oils or other heat-sensitive actives
• Recall procedure tested in the past 12 months with documented results and timing
• Insurance covering product liability and recall costs at appropriate limits, with a current certificate of currency available
• Reference customers in the supplements category willing to confirm consistency, communication and on-time delivery

Australian supplement brands routinely deal with seasonal volume swings (immune-support spikes in autumn, sports nutrition peaks pre-summer), retailer promotional windows that demand short lead times, and the periodic ARTG-driven label change that has to roll through every SKU at once. A single-site co-packer becomes a bottleneck the moment any of these hit at the same time.

A networked partner with business continuity built in can rebalance work across multiple GMP-licensed facilities when one site is at capacity, undergoing an audit, or briefly offline for cleaning validation. The same network model gives genuine fallback for recall situations: if a contamination concern lands on a product, the next batch does not have to wait for the affected line to be cleared.

The TGA does not care which site within a sponsor's manufacturing arrangement performed a given batch, only that every site is licensed and every batch is documented. CleverPak's Australian network includes facilities licensed across the major dose forms, and the platform tracks the licensed-site allocation for every batch automatically, so the audit trail is intact regardless of which site the work landed in.

For brands packing across pharmaceuticals and medical, food and supplements simultaneously, the same orchestration model applies. The differentiator is whether the partner can route the work to a facility with the right licence and certification for each category, without making the customer manage multiple vendor relationships. That is the model the contract packing in Australia market is shifting toward.